FRAMINGHAM, Mass., November 12, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer, will be presenting a corporate overview and update at two upcoming investor conferences.
Stifel 2015 Healthcare Conference at the New York Palace Hotel in New York, NY on Wednesday, November 18, 2015 from 8:45am to 9:25am EST.
27th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York, NY on Tuesday, December 1, 2015 from 3:30pm to 3:50pm EST.
Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a firstin-class, oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.
The Yates Network